Abstract 2709: CD44 inhibits DCIS progression to invasive carcinoma

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2021-07-01 DOI:10.1158/1538-7445.AM2021-2709

Fang Liu, Jun Zhou, Tanima Kundu-Roy, Joseph Wahler, J. So, Yong Lin, Y. Lou, N. Barnard, I. Matsuura, N. Suh

引用次数: 0

查看原文本刊更多论文

摘要2709:CD44抑制DCIS向侵袭性癌的进展

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).